Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Nucleoside Modification. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Advanced synthesis of 1 2 3-O-triacetyl-5-deoxy-D-ribofuranose via patent CN102432642A. Delivers high purity, safety, and cost reduction in antitumor drug manufacturing.
Patent CN118955591B discloses novel nucleoside monomers reducing off-target effects. Enhance supply chain reliability and cost efficiency in oligonucleotide manufacturing.
Novel patent CN115181147B enables high-purity nucleoside intermediates with streamlined synthesis for cost-effective pharmaceutical manufacturing supply chains.
Patent CN110590886B details a novel 6'-nitrile LNA synthesis enhancing nuclease resistance. Discover scalable routes for high-affinity oligonucleotide intermediates.
Patent CN101481399A reveals a cost-effective route for 5'-O-DMTr-anhydrothymidine, offering significant supply chain advantages for radiopharmaceutical manufacturers.
Novel enzymatic route for 2'-O-propynyl-guanosine. Higher yield, simplified process for oligonucleotide manufacturing supply chain.
Patent CN114369124A reveals a novel 4-step synthesis for 2'-substituted pyrimidine nucleosides, offering high purity and scalable manufacturing for nucleic acid drugs.
Patent CN118852303A details a novel aminolysis method for cytidine vinyl phosphate, offering high purity and cost reduction in nucleoside manufacturing for global supply chains.
Advanced synthesis of 4-(2,4,6-trimethylphenoxy)-5-fluorouracil derivatives via patent CN102532227A. Offers cost-effective, scalable routes for high-purity pharmaceutical intermediates.
Patent CN113423714A details a novel sulfonylation route for 3'-O-amino-ribonucleotides, offering improved selectivity and scalability for nucleic acid manufacturing.
Novel synthesis patent CN109053839A enables high-purity nucleoside modifiers. Significant cost reduction and scalable supply chain for antisense drug manufacturing.
Patent CN102115485A discloses N4-modified cytarabine prodrugs enhancing bioavailability and organ specificity for reliable pharmaceutical intermediate supply chains.
Patent CN103467552A reveals a metal-free route for 8-cyclohexyl-2-fluoro-vidarabine. Enhanced purity and scalable manufacturing for anti-leukemia drug development.
Patent CN112661802B reveals a scalable synthesis of 3'-methoxyguanosine, offering cost reduction in mRNA cap analog manufacturing and reliable supply chain solutions.
Patent CN119431334A details a high-yield synthesis of 2'OMe pseudouridine. This method offers significant cost reduction and supply chain reliability for mRNA manufacturing.
Patent CN1133641C details novel AZT prodrugs with enhanced antiviral activity. Offers scalable synthesis for pharmaceutical intermediates.